Thomas Enzler

University of Michigan

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (8)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (4)

David Zhen

Associate Professor of Medicine

Montefiore Medical Center

UNITED STATES

View details

Robyn Gartrell

Assistant Professor of Pediatrics in Division of Pediatric Hematology/Oncology/SCT

Columbia University

UNITED STATES

View details

Danny Yakoub

Chief of Division of Surgical Oncology, Surgical Director - Georgia Cancer Center

Augusta University Medical College of Georgia

UNITED STATES

View details

Codruta (Cody) Chiuzan

Associate Professor

Northwell Health Feinstein Institutes for Medical Research

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Enzler

Research Interests

Explore related searches

Contact this professor

Articles (8)

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.

Esophageal and Esophagogastric Junction Cancers, Version 2.2023

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials

Collaborators (4)

David Zhen

Robyn Gartrell

Danny Yakoub

Codruta (Cody) Chiuzan

Make your next move.